Literature DB >> 8449630

Monitoring dominant germ cell mutations using skeletal dysplasias registered in malformation registries: an international feasibility study.

B Källén1, L B Knudsen, O Mutchinick, P Mastroiacovo, P Lancaster, E Castilla, E Robert.   

Abstract

Using data from seven malformation monitoring systems around the world, the feasibility of monitoring fresh dominant mutations using skeletal dysplasias was explored. Based on a total of over 9.5 million births, 1500 infants with skeletal dysplasias were identified (16 per 100,000). In spite of efforts to get exact diagnoses, an average of 21% were unspecified. Comparisons of rates of specific diagnoses in different programmes suggested that classification differed. By analysing maternal age distribution, estimates were made of the proportion of fresh mutations in different subgroups: conditions regarded as dominant (achondroplasia, thanatophoric dysplasia, spondyloepiphyseal dysplasia) were estimated to consist of 58% fresh mutations--some of the remaining cases were inherited, others were probably misclassified. Among conditions regarded as recessive, only 5% were estimated to be truly dominant mutations. In the total group of skeletal dysplasias, 21% were estimated to be fresh dominant mutations and if osteogenesis imperfecta were excluded, the figure was 31%. By power analyses it was shown that equal monitoring power may be obtained by a programme covering about 45,000 births per year with intensive diagnosis of each individual case of skeletal dysplasia and a programme some three times greater where no specific diagnoses are obtained. An increasing trend in the occurrence of skeletal dysplasias was seen but probably explained by changing ascertainment. An impact of antenatal diagnosis resulting in a decrease in occurrence was also apparent in some programmes.

Entities:  

Mesh:

Year:  1993        PMID: 8449630     DOI: 10.1093/ije/22.1.107

Source DB:  PubMed          Journal:  Int J Epidemiol        ISSN: 0300-5771            Impact factor:   7.196


  7 in total

Review 1.  Osteochondral diseases and fibrodysplasia ossificans progressiva.

Authors:  Antonio Morales-Piga; Frederick S Kaplan
Journal:  Adv Exp Med Biol       Date:  2010       Impact factor: 2.622

2.  The population-based prevalence of achondroplasia and thanatophoric dysplasia in selected regions of the US.

Authors:  D K Waller; A Correa; Tuan M Vo; Y Wang; C Hobbs; P H Langlois; K Pearson; P A Romitti; G M Shaw; J T Hecht
Journal:  Am J Med Genet A       Date:  2008-09-15       Impact factor: 2.802

3.  Thanatophoric dysplasia: case report of an autopsy complemented by postmortem computed tomographic study.

Authors:  Éber Emanuel Mayoral; Regina Schultz; Sérgio Rosemberg; Lisa Suzuki; Luiz Antonio Nunes de Oliveira; Fernando Uliana Kay
Journal:  Autops Case Rep       Date:  2014-06-30

4.  National survey of prevalence and prognosis of thanatophoric dysplasia in Japan.

Authors:  Hideaki Sawai; Kaname Oka; Mariko Ushioda; Gen Nishimura; Takashi Omori; Hironao Numabe; Shinji Kosugi
Journal:  Pediatr Int       Date:  2019-08-27       Impact factor: 1.524

5.  Development and validation of an expanded targeted sequencing panel for non-invasive prenatal diagnosis of sporadic skeletal dysplasia.

Authors:  Ching-Yuan Wang; Yen-An Tang; I-Wen Lee; Fong-Ming Chang; Chun-Wei Chien; Hsien-An Pan; H Sunny Sun
Journal:  BMC Med Genomics       Date:  2021-11-17       Impact factor: 3.063

6.  Rare copy number variants are a common cause of short stature.

Authors:  Diana Zahnleiter; Steffen Uebe; Arif B Ekici; Juliane Hoyer; Antje Wiesener; Dagmar Wieczorek; Erdmute Kunstmann; André Reis; Helmuth-Guenther Doerr; Anita Rauch; Christian T Thiel
Journal:  PLoS Genet       Date:  2013-03-14       Impact factor: 5.917

7.  Birth prevalence of achondroplasia: A systematic literature review and meta-analysis.

Authors:  Pamela K Foreman; Femke van Kessel; Rosa van Hoorn; Judith van den Bosch; Renée Shediac; Sarah Landis
Journal:  Am J Med Genet A       Date:  2020-08-17       Impact factor: 2.802

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.